

Migraine Attack Data Analyses

DEMOGRAPHICS OF PATIENTS

Table 1. Average Age of Patients by Gender

Gender	N	Mean Age
F	12	31.25
M	8	38.00

Table 2. Analysis of Smoking and Alcohol

Smoking		Alcohol	
N	Y	N	Y
16	4	17	3

Table 3. Analysis of Smoking History and Alcohol Consumption

Label	N	Mean	Std Dev
No. of Cigars smoked	30	7.87	1.74
No. of years smoked	30	10.60	3.84
No. of Drinks per week	24	3.42	0.50

VISIT 1

ANALYSIS OF CLINICAL EXAMINATION

Tabel 4. Means of Blood Pressure and Pulse Rate

Label	N	Mean	Std Dev
Pulse	20	75.40	5.32
Systolic Blood Pressure	20	122.20	10.68
Diastolic Blood Pressure	20	75.80	7.81

Table 5. Summary of other diseases

Label	N	Percent
Cardio		
NAD	18	90.00
NS	1	5.00
S1S2N	1	5.00
Respiratory		
Clear NVBS	1	5.00
NAD	19	95.00
Abdomen		
Liver Palpable	1	5.00
NAD	17	85.00
Soft and no mass felt	1	5.00
Soft and non tada	1	5.00
Central Nevrous System		
Clinically N	1	5.00

Label	N	Percent
NAD	19	95.00

Note: No patients were found with Angina, Myoinfa, Allergy and Cerinc

LAB TESTING

Table 6. Anlysis of Patient Blood History Data

Label	N	Mean	Std
SC	20	0.72	0.11
Hemoglobin	19	12.34	1.21
Urea	20	17.56	11.08
White Blood Cells	17	10,670.59	1,382.37
Sodium	13	124.38	7.87
Neutrophils	20	68.85	3.66
Eosinophils	11	4.18	7.63
Basophils	4	0.50	0.58
Potassium	13	4.47	0.32
Lymphocytes	20	27.05	7.21
Sugar	20	111.70	26.32
Monocytes	17	1.94	0.75
Platelets	20	2.22	0.56
SB	20	0.76	0.11
SGOT	20	26.40	17.37
SGPT	20	27.65	22.91

Table 7. Summary of Urine Anlysis, Pregnancy and ECG

Label	N	Percent
Urine Analysis		
Normal	1	6.67
NAD	12	80.00
Within Normal Limits	2	13.33
Pregnancy		
Not Applicable	5	33.33
Negative	10	66.67
ECG		
Clinically N	1	6.67
NAD	1	6.67
Normal	1	6.67
Within Normal Limits	12	80.00

MIGRAINE ATTACK

Table 8. Averages of Time Since Initial Attack (Month), Frequency and Duration

Label	N	Mean	Std Dev
Time Since Initial Attack (Months)	15	108.60	88.11
Frequency Of Attack In A Month	20	5.50	5.50

Label	N	Mean	Std Dev
Duration Of Attack (Hours)	20	171.00	252.52

Table 9. Analysis of Side Effects Due to Migraine Attack

Label	N	Percent
Aura		
N	13	65.00
Y	7	35.00
Nausea		
N	4	20.00
Y	16	80.00
BlurredVision		
N	14	70.00
Y	6	30.00
Photophobia		
N	10	50.00
Y	10	50.00
Phonophobia		
N	6	30.00
Y	14	70.00

Table 10. Analysis of Patient History based on Drug Intake for Migraine

Drug Condition	Drug	Generic	Dose	Continued	Dose	Discontinuation	Duration
migrane	flenarin		1T1D	N		30days	180days
migrane			1BD	N		30days	180days
migrane	sinarest		1Tab	N		7days	60days
migrane	sumo		1Tab	N		7days	60days
migrane	clotan		200mg	N		3days	60days
migrane	diclofenac		50mg bd	Y	100 per day		365days
migrane	paracetamol		650mg	N		14days	180days
migrane	ibuprofen		400mg	N		14days	365days
migrane	sibellium	flunarazine	10mg OD	N		7days	30days
migrane	indual	proprawl 40mg	40mg OD	N		7days	30days
migrane	proxylon			N			SOS
migrane	suminat	sundriptan	50mg OD	N		2days	1days
migrane							
migrane	AMT 25	ametrypliline	25mg	N		3days	7days
migrane	Dolo	paracetamol	650mg	N		1days	SOS
migrane	proxylon			N			
migrane	sibdlium	flunorazine		N			
migrane	brufen	ibuprofen	400				SOS
migrane	vasograin	ergotamine caffeine paracetamal	1tab	Y	1tabperattk		2190days
migrane	sibellium			N		2days	30days
migrane	dolopar			N		7days	on and off
migrane	sumo	paracetamal and nimesulide		N		7days	365days on&off
migrane	indenal	proprawl	40mg	N		7days	3days

Drug Condition	Drug	Generic	Dose	Continued	Dose	Discontinuation	Duration
migrane	sibellium	flunerozine	10mg	N		7days	3days
migrane	duodil			N		7days	3days
migrane							
migrane	dolo	paracetamal	650mg	N		30days	180days
migrane	crocine	paracetamal	500mg	N		15days	90days
migrane		flurazine		N		14days	180days
migrane	dolo		650mg	N		14days	180days

Table 11. Analysis of Patient History based on Drug Intake for other than Migraine

Drug Condition	Drug	Generic	Dose	Continued	Dose	Discontinuation	Duration
others	neupro		20mg BD	N		180days	7days
others	theoasthalin		on and off				9125days
others	asthalin inhaler						3650days

VISIT 2

ANALYSIS OF CLINICAL EXAMINATION

Tabel 12. Means of Blood Pressure and Pulse Rate

Label	N	Mean	Std Dev
Pulse	20	76.80	5.33
Systolic Blood Pressure	20	123.90	9.83
Diastolic Blood Pressure	20	78.40	8.32

Table 13. Summary of other diseases

Label	N	Percent
Cardio		
NAD	17	85.00
S1S2N	1	5.00
WNL	2	10.00
Respiratory		
N	1	5.00
NAD	17	85.00
NVBS	1	5.00
WNL	1	5.00
Abdomen		
Clinically N	1	5.00
NAD	18	90.00
WNL	1	5.00
Central Nervous System		
Clinically N	2	10.00
NAD	17	85.00
WNL	1	5.00

Note: No patients were found with Angina, Myoinfa, Allergy and Cerinc

[Evaluation of Time Difference between Migraine Attack Time and Migraine Attack Reported Time, Nausea and Blood Pressure \(Table 14 – Table 22\)](#)

Table 14. Initial Evaluation

Label	N	Mean	Std Dev
Evaluation of Nausea	120	12.08	19.05
Time Difference between MAT and MART	19	-94.74	45.96

Note: MAT - Migraine Attack Time. MART - Migraine Attack Reported Time.

Table 16. Evaluation After 1 Hour

Label	N	Mean	Std Dev
Systolic Blood Pressure	20	121.30	9.74
Diastolic Blood Pressure	20	76.30	5.81
Evaluation of Nausea	20	15.25	18.60

Table 16. Evaluation After 1 Hour

Label	N	Mean	Std Dev
Systolic Blood Pressure	20	121.50	8.13
Diastolic Blood Pressure	20	77.30	5.32
Evaluation of Nausea	20	10.25	17.28

Table 17. Evaluation After 2 Hour

Label	N	Mean	Std Dev
Systolic Blood Pressure	20	120.50	8.26
Diastolic Blood Pressure	20	76.90	4.23
Evaluation of Nausea	20	6.75	14.89

Table 18. Evaluation After 3 Hour

Label	N	Mean	Std Dev
Systolic Blood Pressure	20	119.10	7.06
Diastolic Blood Pressure	20	77.00	4.52
Evaluation of Nausea	20	7.50	20.74

Table 19. Evaluation After 4 Hours

Label	N	Mean	Std Dev
Systolic Blood Pressure	20	119.80	7.31
Diastolic Blood Pressure	20	77.60	4.03
Evaluation of Nausea	20	1.00	4.47

Table 20. Evaluation After 6 Hours

Label	N	Mean	Std Dev
Systolic Blood Pressure	20	124.20	6.74
Diastolic Blood Pressure	20	77.70	4.78

Table 21. Evaluation between 6-24 Hours

Label	N	Mean	Std Dev
Systolic Blood Pressure	20	122.00	6.96
Diastolic Blood Pressure	20	77.90	4.28

SUMMARY OF PATIENT STATUS

Table 22. Analysis of Functional Capability and Global Evaluation

Label	N	Percent
Functional Disability		
0	14	70.00
1	2	10.00
2	4	20.00
Patient Global Evaluation		
excellent	9	45.00
good	5	25.00
poor	2	10.00
satisfactory	4	20.00
Investigation Global Evaluation		
effective	4	20.00
not effective	5	25.00
very effective	11	55.00
Patient Study Status		
Y	20	100.00